Jonathan Meyer, MD discusses age, sex, duration of treatment, comorbidities, and other risk factors.
Supported by an educational grant from Neurocrine Biosciences, Inc.
All Podcasts
Jonathan Meyer, MD compares first-generation and second-generation antipsychotics in TD risk.
Dr. Meyer discusses how dopamine receptor changes contribute to the development of tardive dyskinesia and the potentially detrimental effects of some treatments.
Hello colleagues, welcome to this podcast. Today, we'll discuss "Beyond the Side Effects: Understanding and Addressing Tardive Dyskinesia." Our focus will be on helping healthcare providers recognize the persistence and pathophysiology of tardive dyskinesia and differentiate it from common medication side effects.
Welcome back, colleagues, to our discussion on the hidden toll of tardive dyskinesia beyond movement symptoms. I look forward to exploring this topic, as it reflects my over 30 years in the field and my initial unawareness of the broader impact of tardive dyskinesia.
Welcome, colleagues, to our discussion on mastering VMAT2 inhibitors with the aim of optimizing treatment strategies for tardive dyskinesia.